Targets › CD40LG
5 programs from 5 companies in 9 trials: 4 Phase 1, 3 Phase 3, 2 Phase 2; Immunology, Oncology, Genitourinary; next expected readout Dec 2026.
Cytokine that acts as a ligand to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production. (UniProt, P29965)
Open in Phaseline: the race on CD40LG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amgen | Dazodalibep CD40 ligand antagonist | CD40LG | Phase 3 | Sjögren's Syndrome (SS); Sjögren's Syndrome; Lupus Nephritis | Dec 2026 |
| UCB Biopharma SRL | dapirolizumab pegol CD40 ligand inhibitor | CD40LG | Phase 3 | Systemic Lupus Erythematosus | May 2028 |
| AbbVie | Ravagalimab CD40 ligand antagonist | CD40LG | Phase 2 | Rheumatoid Arthritis | Feb 2027 |
| Eledon Pharmaceuticals | Tegoprubart (AT-1501) CD40 ligand inhibitor | CD40LG | Phase 1 | Prevention of Rejection in Kidney Transplant; Type 1 Diabetes Mellitus; Diabete Type 1 | Jan 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | CD40L-augmented TIL Tumor-infiltrating lymphocytes engineered with CD40L co-stimulatory molecule for enhanced | CD40LG | Phase 1 | Melanoma | May 2029 |
Systemic Lupus Erythematosus (1) Melanoma (1) Rheumatoid Arthritis (1) Prevention of Rejection in Kidney Transplant (1) Type 1 Diabetes Mellitus (1) Diabete Type 1 (1) Sjögren's Syndrome (SS) (1) Sjögren's Syndrome (1) Lupus Nephritis (1)
small molecule (3), mixed (1), antibody (1)
UCB Biopharma SRL (1) H. Lee Moffitt Cancer Center and Research Institute (1) AbbVie (1) Eledon Pharmaceuticals (1) Amgen (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.